Transparency Market Research in its new report titled, “Ovulation Inducing Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2026,” provides key insights on the ovulation inducing drugs market. The TMR report anticipates that the rise in number of patients opting for IVF will drive the ovulation inducing drugs market during the forecast period i.e, 2018-2026. Moreover, key suppliers are introducing new medications such as recombinant hormones and gonadotropins. This is likely to fuel the growth of the ovulation inducing drugs market. However, high cost of IVF procedure and low success rates are the major factors likely to restrain the global ovulation inducing drugs market. Furthermore, large number of small and medium scale manufacturers of ovulation inducing drugs at regional levels has led to a fragmented ovulation inducing drugs market, says the report.
The TMR report has segmented the global ovulation inducing drugs market based on drug class, distribution channel, and region. On the basis of drug class, the global ovulation inducing drugs market is bifurcated into hormones and pharmaceuticals. The hormones segment is classified into follicle stimulating hormone (FSH), human menopausal gonadotropin (hMG), and human chorionic gonadotropin (hCG). hMGs are combination of FSH and luteinizing hormone (LH) offering better efficiency and low adverse effects. The pharmaceuticals segment can be divided into gonadotropin releasing hormone (GnRH) agonists and GnRH antagonists. These drugs stimulate the production of gonadotropin hormones such a FSH and LH to augment the ovulation process. On the basis of distribution channel, the global ovulation inducing drugs market is segregated into hospital pharmacies, independent pharmacies, and online pharmacies. In some markets, IVF centers dispense these medications to patients.
On the geographical perspective, the global ovulation inducing drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Among these, North America is projected to account for the largest share of the global ovulation inducing drugs market during the forecast period, due to high adoption of IVF and ART techniques. Europe is anticipated to account for a significant share of the global ovulation inducing drugs market during the forecast period. Well-established health care infrastructure and trend for fertility tourism in countries in Central and Eastern Europe are the key factors driving the embryo transfer devices market in the region. Increase in expenditure to develop health care infrastructure and rise in private health care expenditure in emerging markets such as China and India are anticipated to boost the market in Asia Pacific. Changing lifestyle and rising rates of infertility are the major factors that contribute to the growth of the ovulation inducing drugs market in developing countries.
Some of the key players operating in the global ovulation inducing drugs market are profiled in this report and these include Sanofi, EMD Serono, Inc., Ferring Pharmaceuticals, Inc., Fresenius Kabi AG, Merck & Co., Inc., Sun Pharmaceuticals Industries Ltd., Serum Institute of India Ltd., and Glenmark Pharmaceuticals Ltd.
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453